- Fund Type: Open-End Fund
- Objective: Growth and Income
- Asset Class: Equity
- Geographic Focus: Global
Snapshot for Columbus Global Trend Fund (COLUMEU)
| Year To Date: | +2.28% | 3-Month: | +0.27% | 3-Year: | - | 52-Week Range: | 88.27 - 99.66 |
|---|---|---|---|---|---|---|---|
| 1-Month: | +0.28% | 1-Year: | +3.38% | 5-Year: | - | Beta vs DJST: | 0.62 |
Fund Profile & Information for COLUMEU
Columbus Global Trend Fund is an open-end investment fund incorporated in Liechtenstein. The Fund's objective is to achieve long-term continual returns while minimizing risk. The Fund invests worldwide in stocks from varying sectors.
| Inception Date: | 01-07-2011 | Telephone: | 423 235 04 50 TEL |
|---|---|---|---|
| Managers: | - | ||
| Web Site: | www.ifmfunds.com | ||
Fundamentals for COLUMEU
| NAV | (on 2013-05-17) 97.52 |
|---|---|
| Assets (M) | (on 2013-05-17) 32.03 |
| Fund Leveraged | N |
| Minimum Investment | - |
| Minimum Subsequent Investment | - |
Dividends for COLUMEU
No dividends reported
Fees & Expenses for COLUMEU
| Front Load | - |
|---|---|
| Back Load | 0.00 |
| Current Mgmt Fee | - |
| Redemption Fee | 0.00 |
| 12b1 Fee | - |
| Expense Ratio | - |
Top Fund Holdings for COLUMEU
Filing Date: 03/22/2013| Name | Position | Value | % of Total |
|---|---|---|---|
| Givaudan SA | 2,000 | 2,406,000 | 7.696% |
| Arsago Brazil Equity Value | 21,000 | 1,708,350 | 5.465% |
| Essilor International SA | 14,000 | 1,511,215 | 4.834% |
| Cie Financiere Richemont SA | 20,000 | 1,463,000 | 4.680% |
| Novartis AG | 20,000 | 1,329,000 | 4.251% |
| ABB Ltd | 60,000 | 1,273,200 | 4.073% |
| Lindt & Spruengli AG | 30 | 1,231,800 | 3.940% |
| Lyxor ETF Brazil Ibovespa | 50,000 | 1,216,020 | 3.890% |
| Zurich Insurance Group AG | 4,500 | 1,190,250 | 3.807% |
| Syngenta AG | 3,000 | 1,188,000 | 3.800% |
Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
- 1
- 2
- 3
- 4
- 5
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page